Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Pyxis Oncology Inc (NASDAQ:PYXS) agreed to acquire Apexigen Inc (NASDAQ:APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share
  • Apexigen went public in a blank-check deal just last summer.
  • For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million.
  • In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%.
  • "This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfizer," said Lara S. Sullivan, President & CEO of Pyxis Oncology.
  • Pyxis Oncology ended Q1 FY23 with approximately $150.8 million in cash.
  • Effective June 15, 2023, Jay Feingold will step down as Chief Medical Officer to pursue other opportunities. He will remain an advisor to Pyxis Oncology until a successor is named.
  • Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders.
  • The transaction is anticipated to close by mid-2023.
  • The combined company will trade on Nasdaq under the ticker symbol PYXS. The existing Pyxis Oncology leadership team will continue, including Lara S. Sullivan as President & CEO, Pamela Connealy as CFO & COO, and Jan Pinkas as Chief Scientific Officer.
  • In 2021, Pyxis Oncology entered into a worldwide license agreement with Pfizer Inc (NYSE:PFE) for two antibody-drug conjugate (ADC) candidates and a license to Pfizer's ADC technology platform.
  • Price Action: APGN shares are up 39.5% at $0.56, and PYXS shares are down 8.92% at $3.40 on the last check Wednesday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechM&ANewsPenny StocksHealth CareMoversGeneralBriefs